Best GLP-1 for Fatty Liver: Ranked
Fatty liver disease had almost no effective drug treatments until very recently. One GLP-1 now carries an FDA approval for it - and that approval has specific limits worth understanding before you assume it applies to you.
Last updated: August 3, 2026
Start Here: Only Wegovy Is Approved for MASH
The FDA granted accelerated approval to Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH and moderate to advanced liver fibrosis - the first GLP-1 therapy approved for this progressive liver disease. If you have been properly diagnosed and staged, that indication is your strongest route to coverage. Pursue it first.
Best Value if Coverage Fails: Coreage Rx
Most people with fatty liver do not meet the narrow MASH-with-fibrosis criteria - they have earlier-stage disease, which is still worth treating. And plenty who do qualify get denied anyway. In both cases, weight loss remains the single most effective intervention for hepatic fat, whichever GLP-1 delivers it.
Coreage Rx is our top recommendation for affordable access. Physician-supervised compounded semaglutide starts at $249/month all-inclusive - consultation, medication, shipping, and ongoing dose management in one flat price, with no insurance required.
Why Coreage Rx Ranks First for Access
- Semaglutide - the same molecule that earned the MASH approval
- No insurance battle, which matters when MASH prior authorisations are slow
- $249/month all-in with no membership fee stacked on top
- Works for earlier-stage fatty liver that falls outside the narrow approval criteria
- US board-certified physicians managing dosing and monitoring
- Sustainable long term - hepatic fat returns if weight does
Fatty liver disease requires a doctor, not a website. MASH diagnosis and fibrosis staging need proper assessment - typically imaging such as elastography, blood-based fibrosis scores, and sometimes biopsy. Do not self-diagnose, and do not treat abnormal liver enzymes as something to manage on your own. If you have liver disease, a hepatologist or gastroenterologist should be involved.
The Rankings
| Rank | Option | MASH Indication? | Monthly Cost |
|---|---|---|---|
| 🏆 Best Value | Coreage Rx (compounded semaglutide) ⭐ | No - not an approved product | From $249 all-in |
| #1 for Coverage | Wegovy (semaglutide 2.4 mg) | Yes - only approved option | $149-$399 |
| #2 | Zepbound (tirzepatide) | No | $299-$449 |
| #3 | Wegovy HD (semaglutide 7.2 mg) | No - approval is for 2.4 mg | $399 |
| #4 | Wegovy Pill / Foundayo | No | $149-$349 |
If you have diagnosed MASH with moderate to advanced fibrosis, Wegovy 2.4 mg is the correct answer - it is the only product with the indication, and that indication is what unlocks coverage. Do not settle for an alternative before pursuing it.
If you have earlier-stage fatty liver or you are denied, an affordable semaglutide programme is the practical route, since weight loss is the underlying mechanism regardless of branding.
MASLD, MASH, NAFLD: The Terminology
The naming changed recently and it causes real confusion, including in search results.
| Term | What It Means |
|---|---|
| MASLD | Metabolic dysfunction-associated steatotic liver disease - fat in the liver, the broader and earlier condition. Formerly NAFLD. |
| MASH | Metabolic dysfunction-associated steatohepatitis - fat plus inflammation and liver cell damage. The more serious form. Formerly NASH. |
| Fibrosis | Scarring from ongoing damage, staged F0 to F4. F4 is cirrhosis. |
| NAFLD / NASH | The older names for MASLD and MASH. Still widely used. |
The distinction matters for the approval. Wegovy's indication covers MASH with moderate to advanced fibrosis - not simple fatty liver, and not MASH without meaningful fibrosis. Someone told they have "a fatty liver" on an ultrasound has probably not been staged and may not qualify.
What the Wegovy Approval Actually Covers
The FDA granted accelerated approval to Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH and moderate to advanced liver fibrosis. Three limits are built into that phrasing:
- Noncirrhotic. The indication does not extend to patients who have already developed cirrhosis (F4).
- MASH, not simple MASLD. Fat alone is not enough - there must be steatohepatitis, meaning inflammation and cell damage.
- Moderate to advanced fibrosis. Early-stage fibrosis falls outside it.
What Accelerated Approval Means
Accelerated approval is granted based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than on final outcomes like liver failure, transplant, or death - because waiting for those in a slowly progressing disease would take many years. Confirmatory trials continue after approval.
This is a real approval that supports prescribing and coverage, and it is a genuine milestone for a disease that had almost no drug options. It is worth understanding, though, that the evidence standard differs from a standard approval, and that confirmatory data is still accumulating. Your hepatologist will weigh that in context.
Why GLP-1s Work on Liver Fat
MASLD and MASH are metabolic diseases, driven by the same insulin resistance and visceral adiposity that drive type 2 diabetes. GLP-1s intervene on those directly.
- Weight loss reduces hepatic fat. This is the dominant mechanism and the best-established treatment for fatty liver of any kind.
- Improved insulin sensitivity reduces the flux of fatty acids into the liver.
- Reduced visceral adiposity. Visceral fat drains directly to the liver via the portal circulation, so reducing it lowers the liver's fat and inflammatory burden.
- Lower systemic inflammation, which matters because inflammation is what distinguishes MASH from simple fat accumulation.
The visceral fat connection is why our belly fat guide overlaps with this one - they are largely the same tissue problem viewed from different angles.
Worth noting for the pipeline: the investigational triple agonist retatrutide includes glucagon receptor activation, which promotes fat breakdown in the liver specifically - and hepatic fat is drawing significant research interest as a target for that drug class. See our retatrutide guide. That is future-tense, not an option today.
Getting Diagnosed and Staged
You cannot claim the MASH indication without documentation, and fatty liver is frequently silent - many people have it without knowing.
- Liver enzymes are a starting point, not an answer. Elevated ALT and AST may prompt investigation, but they can be normal even in significant disease.
- Imaging identifies fat. Ultrasound commonly detects steatosis, which is how most people first hear they have "a fatty liver."
- Fibrosis staging is the critical step. This is what determines whether the indication applies. Elastography - FibroScan or MR elastography - and blood-based fibrosis scores are commonly used.
- Biopsy in some cases. Still used where non-invasive staging is unclear, particularly to confirm steatohepatitis versus simple steatosis.
- See a hepatologist or gastroenterologist. Primary care can start the workup, but staging and treatment decisions for MASH belong with a specialist.
If you have obesity plus type 2 diabetes, ask about liver assessment. That combination carries substantially elevated MASLD and MASH risk, and the disease is often silent until fibrosis is advanced. Knowing your fibrosis stage is worth having regardless of whether you pursue medication.
Using the MASH Indication for Coverage
Many plans exclude weight loss medications as a category. Almost none exclude treatment for progressive liver disease. That asymmetry is the opportunity.
- Get properly staged. Documented MASH with moderate to advanced fibrosis, ideally with elastography or biopsy results in your record.
- Have your prescriber request Wegovy specifically - the approval belongs to semaglutide 2.4 mg under that brand, not to Ozempic or Wegovy HD.
- Submit under the MASH indication, not the obesity indication.
- Include the full metabolic picture - type 2 diabetes, hypertension, dyslipidaemia all strengthen the case.
- Appeal a first denial and request a peer-to-peer review if the written appeal fails. Having a hepatologist speak to the plan's reviewer carries weight.
If You Are Denied or Do Not Qualify: From $249/month
Appeals take time, and liver disease progresses while you wait. Coreage Rx provides physician-supervised compounded semaglutide from $249/month all-inclusive with no insurance required - a practical route while you pursue coverage, or if your stage falls outside the approval.
An honest caveat: compounded semaglutide is not an FDA-approved product and does not carry the MASH indication. If you have documented MASH with fibrosis, the brand-name product with the matching indication is the clinically appropriate choice and worth fighting for through appeals. A compounded route is a fallback for access, not a substitute for indicated disease treatment - and your hepatologist should know what you are taking either way.
What Else Actually Matters
Medication is one part of managing fatty liver. These are not optional extras:
- Alcohol. Even modest intake adds burden to a liver already under stress. Discuss your specific situation with your hepatologist - for many with MASH, the advice is abstinence. Note also that GLP-1s frequently reduce the desire to drink, which some patients find helpful here. See our guide on GLP-1s and alcohol cravings.
- Weight loss magnitude. Larger reductions produce greater improvement in hepatic fat and inflammation.
- Protein and resistance training. Preserving lean mass matters here as everywhere - see our muscle loss guide.
- Fructose and ultra-processed food. Both are implicated in hepatic fat accumulation. Our ideal diet guide covers the nutrition framework.
- Medication review. Some drugs and supplements burden the liver. Make sure your full list is reviewed - including anything over the counter.
- Ongoing monitoring. Repeat staging is how you know whether treatment is working. Enzymes alone will not tell you.
Frequently Asked Questions
Which GLP-1 is approved for fatty liver?
Wegovy (semaglutide 2.4 mg) received FDA accelerated approval for adults with noncirrhotic MASH and moderate to advanced liver fibrosis - the first GLP-1 approved for this progressive liver disease. No other GLP-1 carries a liver indication. Note that the approval is specific to Wegovy at 2.4 mg, not to Ozempic or Wegovy HD.
Do I qualify if I just have a fatty liver?
Probably not under this specific indication. It requires MASH - fat plus inflammation and liver cell damage - together with moderate to advanced fibrosis, and excludes patients who have developed cirrhosis. Simple fatty liver (MASLD) detected on ultrasound without staging falls outside it. That said, weight loss remains the best-established treatment for fatty liver at any stage, so treatment can still be worthwhile through another route.
What is the difference between MASLD and MASH?
MASLD (formerly NAFLD) is fat accumulation in the liver - the broader, earlier condition. MASH (formerly NASH) is fat plus inflammation and liver cell damage, the more serious form that can progress to fibrosis, cirrhosis, and liver failure. Fibrosis is the scarring that results, staged F0 to F4, with F4 being cirrhosis. The Wegovy approval covers MASH with moderate to advanced fibrosis specifically.
How do I get diagnosed with MASH?
Liver enzymes may prompt investigation but can be normal even in significant disease. Imaging such as ultrasound detects fat. The critical step is fibrosis staging - typically elastography (FibroScan or MR elastography) and blood-based fibrosis scores, with biopsy used in some cases to confirm steatohepatitis. A hepatologist or gastroenterologist should direct this. If you have obesity plus type 2 diabetes, ask about liver assessment; MASH is often silent until fibrosis is advanced.
Will insurance cover a GLP-1 for fatty liver?
It is a stronger claim than an obesity-only request, since many plans exclude weight loss drugs as a category while progressive liver disease is a distinct condition with an FDA-approved indication behind it. Have your prescriber request Wegovy specifically, submit under the MASH indication with documented fibrosis staging, include your full metabolic picture, and appeal a first denial - a peer-to-peer review with a hepatologist carries weight.
What does accelerated approval mean here?
It means approval was granted based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than on final outcomes like liver failure or death - because waiting for those in a slowly progressing disease would take many years. Confirmatory trials continue after approval. It is a real approval supporting prescribing and coverage, but the evidence standard differs from a standard approval.
Can I drink alcohol with fatty liver on a GLP-1?
This is a question for your hepatologist rather than a general guideline - for many people with MASH the advice is abstinence, since even modest intake adds burden to a liver already under stress. Worth knowing: GLP-1s frequently reduce the desire to drink, with trial evidence showing significantly reduced alcohol craving, which some patients find makes cutting back considerably easier.
Does compounded semaglutide treat MASH?
Compounded semaglutide is not an FDA-approved product and does not carry the MASH indication, so it cannot be prescribed for that purpose in the way branded Wegovy can. It contains the same molecule and produces the weight loss that drives hepatic fat reduction, which is why it is a reasonable access route for people denied coverage or with earlier-stage disease. If you have documented MASH with fibrosis, pursue the approved product first, and keep your hepatologist informed of whatever you take.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Fatty liver disease, MASH, and liver fibrosis require diagnosis, staging, and management by qualified clinicians - typically a hepatologist or gastroenterologist. Do not self-diagnose or self-treat liver disease. Only Wegovy (semaglutide 2.4 mg) holds FDA accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis; use of other GLP-1 medications for liver disease would be off-label, and compounded medications are not FDA-approved products and carry no approved indications. Approval details and labelling reflect publicly available information at the time of writing. Rankings reflect our editorial assessment and may not suit your circumstances. HealthyPound may receive compensation from affiliate partners mentioned in this article, including Coreage Rx. See our affiliate disclosure and full medical disclaimer.